ATE526331T1 - Pyrrolopyrimidine für pharmazeutische zusammensetzungen - Google Patents

Pyrrolopyrimidine für pharmazeutische zusammensetzungen

Info

Publication number
ATE526331T1
ATE526331T1 AT07785972T AT07785972T ATE526331T1 AT E526331 T1 ATE526331 T1 AT E526331T1 AT 07785972 T AT07785972 T AT 07785972T AT 07785972 T AT07785972 T AT 07785972T AT E526331 T1 ATE526331 T1 AT E526331T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
pyrrolopyrimidines
pyrrolopyrimidine compounds
relates
present
Prior art date
Application number
AT07785972T
Other languages
English (en)
Inventor
Stefan Jaekel
Tanja Reuter
Stephen Murfin
Thomas Coulter
Steven Taylor
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE526331T1 publication Critical patent/ATE526331T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
AT07785972T 2006-07-10 2007-07-10 Pyrrolopyrimidine für pharmazeutische zusammensetzungen ATE526331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014297A EP1889847A1 (de) 2006-07-10 2006-07-10 Pyrrolopyrimidine zur pharmazeutischen Anwendung
PCT/EP2007/006109 WO2008006547A2 (en) 2006-07-10 2007-07-10 Pyrrolopyrimidines for pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE526331T1 true ATE526331T1 (de) 2011-10-15

Family

ID=37496429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07785972T ATE526331T1 (de) 2006-07-10 2007-07-10 Pyrrolopyrimidine für pharmazeutische zusammensetzungen

Country Status (16)

Country Link
US (1) US8697713B2 (de)
EP (2) EP1889847A1 (de)
JP (1) JP5331951B2 (de)
KR (1) KR20090039757A (de)
CN (1) CN101511837A (de)
AT (1) ATE526331T1 (de)
AU (1) AU2007271928A1 (de)
BR (1) BRPI0712882A2 (de)
CA (1) CA2690277A1 (de)
CO (1) CO6150162A2 (de)
EA (1) EA200900136A1 (de)
IL (1) IL196391A0 (de)
MX (1) MX2009000333A (de)
NO (1) NO20090029L (de)
WO (1) WO2008006547A2 (de)
ZA (1) ZA200810785B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
AU2009286734A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
BR112012021364A2 (pt) * 2010-02-26 2016-10-25 Boehringer Ingelheim Int "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
UY33245A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
JP2013520473A (ja) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のＭｎｋ１／Ｍｎｋ２阻害活性を有するハロゲン又はシアノ置換されたチエノ［２，３−ｄ］ピリミジン
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
KR101286743B1 (ko) * 2011-02-18 2013-07-15 충남대학교산학협력단 페노피브레이트를 함유하는 패혈증 예방용 약학 조성물
JP6147761B2 (ja) * 2011-12-12 2017-06-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アミノ置換イミダゾピリダジン
US20150133426A1 (en) * 2012-05-21 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
US11186575B2 (en) 2012-08-07 2021-11-30 Alber Einslein College of Medicine Treatment of helicobacter pylori infections
WO2014048869A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
EP2900670A1 (de) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituierte indazolpyrrolopyrimidine zur behandlung von hyperfoliferativen erkrankungen
JP6306035B2 (ja) * 2012-11-09 2018-04-04 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシミン置換キナゾリン
ES2653419T3 (es) * 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Pirazolopirimidinilamino-indazoles sustituidos
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3013805B1 (de) * 2013-06-28 2018-02-21 Evotec International GmbH Sulfoximin substituierte chinazoline und ihre verwendung als mnk1 und/oder mnk2 kinase inhibitoren
PE20160125A1 (es) * 2013-07-08 2016-03-17 Bayer Pharma AG Pirazolpiridinas sustituidas
WO2015091156A1 (en) * 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
CA2944103A1 (en) * 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
CN104225597A (zh) * 2014-09-29 2014-12-24 武汉大学 Mapk信号整合激酶1在治疗动脉粥样硬化中的功能和应用
PL3244891T3 (pl) * 2015-01-16 2022-12-27 The General Hospital Corporation Związki poprawiające splicing mRNA
DK3285809T3 (da) 2015-04-20 2019-11-18 Effector Therapeutics Inc Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
BR112018002399A2 (pt) 2015-08-06 2018-09-25 Chimerix, Inc. nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais
SG11201803242TA (en) * 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
CN108602814A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
WO2017087808A1 (en) * 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3397774A1 (de) 2015-12-31 2018-11-07 Effector Therapeutics Inc. Mnk-biomarker und verwendungen davon
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions
GB2550977B (en) 2016-05-31 2020-07-22 Cirrus Logic Int Semiconductor Ltd Monitoring of devices
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
JP2020507588A (ja) 2017-02-14 2020-03-12 イーフェクター セラピューティクス， インコーポレイテッド ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
ES3011607T3 (en) 2017-09-21 2025-04-07 Chimerix Inc Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
BR112021007745A2 (pt) 2018-10-24 2021-07-27 Effector Therapeutics, Inc. formas cristalinas de inibidores de mnk
CN110483527A (zh) * 2019-09-09 2019-11-22 陕西科技大学 一种4-氯吡咯[2,3-d]嘧啶取代化合物及其合成方法
US20220370463A1 (en) * 2019-09-19 2022-11-24 New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de) 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
EP0729758A3 (de) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidine und Pyrrolopyrimidine zur Behandlung von neuronalen und anderen Krankheiten
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6643277B2 (en) 2000-06-29 2003-11-04 Harris Broadband Wireless Access, Inc. Frequency re-use for point to multipoint applications
MXPA03009925A (es) 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
DE60238929D1 (de) 2001-10-29 2011-02-24 Boehringer Ingelheim Int Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20050012622A1 (en) 2003-05-19 2005-01-20 Sutton William R. Monitoring and control of sleep cycles
WO2004106339A2 (en) 2003-05-28 2004-12-09 Università Degli Studi Di Siena 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
KR20060021905A (ko) 2003-06-20 2006-03-08 셀테크 알앤디 리미티드 키나아제 억제제로서의 티에노피리돈 유도체
WO2005010008A1 (en) 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2005067908A2 (en) 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1724268A4 (de) 2004-02-20 2010-04-21 Kirin Pharma Kk Verbindungen mit tgf-beta-hemmender wirkung und pharmazeutische zusammensetzung, die diese enthält
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1773826A4 (de) 2004-07-02 2009-06-03 Exelixis Inc C-met-modulatoren und anwendungsverfahren
EP1746099A1 (de) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 Inhibitoren
JP5328342B2 (ja) 2005-03-08 2013-10-30 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｎｋ−１タンパク質およびＭｎｋ−２タンパク質の結晶学的構造
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
EP1899353A1 (de) 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidine für pharmazeutische zusammensetzungen
US20070213305A1 (en) 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056215A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and the use thereof
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
CN1990479A (zh) 2005-12-29 2007-07-04 中国科学院上海药物研究所 3－烷氧取代－2,5,7－三取代苯并吡喃－4－酮类化合物及其制备方法和包含该类化合物的药物组合物
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
RU2009101911A (ru) 2006-06-22 2010-07-27 Биовитрум Аб (Пабл) (Se) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
EP2219649A2 (de) 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Verwendung von mnk-inhibitoren zur behandlung von alzheimer-krankheit
JP4630942B2 (ja) 2008-01-25 2011-02-09 シャープ株式会社 移動局装置、データ送信方法及びプログラム
US20100015708A1 (en) 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
AU2009286734A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
BR112012021364A2 (pt) 2010-02-26 2016-10-25 Boehringer Ingelheim Int "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
UY33245A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
JP2013520473A (ja) 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のＭｎｋ１／Ｍｎｋ２阻害活性を有するハロゲン又はシアノ置換されたチエノ［２，３−ｄ］ピリミジン
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2583015T3 (es) 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
CA2690277A1 (en) 2008-01-17
BRPI0712882A2 (pt) 2012-10-09
WO2008006547A2 (en) 2008-01-17
NO20090029L (no) 2009-01-28
JP2009542749A (ja) 2009-12-03
WO2008006547A3 (en) 2008-03-06
KR20090039757A (ko) 2009-04-22
EP2041137B1 (de) 2011-09-28
ZA200810785B (en) 2009-10-28
US20100105708A1 (en) 2010-04-29
CN101511837A (zh) 2009-08-19
EP2041137A2 (de) 2009-04-01
IL196391A0 (en) 2009-09-22
CO6150162A2 (es) 2010-04-20
MX2009000333A (es) 2009-03-13
EA200900136A1 (ru) 2009-06-30
US8697713B2 (en) 2014-04-15
JP5331951B2 (ja) 2013-10-30
EP1889847A1 (de) 2008-02-20
AU2007271928A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
ATE526331T1 (de) Pyrrolopyrimidine für pharmazeutische zusammensetzungen
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
WO2006066937A3 (en) Mnk1 or mnk2 inhibitors
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
WO2007115620A3 (de) Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
GB0625648D0 (en) Compounds
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
TW200730506A (en) Compounds and uses thereof
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties